Ivey Business School (Canada)
-
Measuring Impairment at Dofasco
Mary Gillett; Mary-Jane MastrandreaCase IVEY-9B09B017-EAccounting and ControlIn December 2008, the ArcelorMittal Dofasco (Dofasco) accounting team was facing a significant challenge. In the past few years, Dofasco had undergone significant ownership changes, and when the firm had first been acquired the market had placed a premium share value on the Dofasco subsidiary. In light of a recent economic downturn, the accounting team was required to reassess the values assigned to the subsidiary's net assets. Dismal forecasted ...Starting at €8.20
-
Calgary Drop-In Centre: Donor Information System
Derrick Neufeld; Deb Elkink; Michelle Woo; Dennis Dupuis; Dan HausermannCase IVEY-9B17E003-EInformation TechnologiesIn the spring of 2016, the director of finance and administration for the Calgary Drop-In & Rehab Centre was frustrated with the organization’s legacy donor and volunteer information system. The technology platform was outdated, data integrity was out of control, costs were spiralling, and most importantly, required information was not available on demand. The director was concerned that these issues with the organization’s information systems wo...Starting at €8.20
-
Mate1.com: Digital Dating Dilemma
Derrick Neufeld; Charles Wasserman; Dharsana Vijayaratnam; Thomas Yuk; Sharon Bir; Deb ElkinkCase IVEY-9B17E015-EEntrepreneurship, Information TechnologiesIn 2017, a successful online dating company, Mate1.com, based in Montreal, was pursuing a two-year goal of increasing revenue by 50 per cent and net operating margin by 15 per cent. However, its ambitions were being hampered by unavoidably high advertising costs, an inadequate reporting system, and a maturing industry life cycle. Should the firm explore new business models and consider acquiring a competitor—or was it time to divest and sell the ...Starting at €8.20
-
Accounting at Biovail - Revised
Mary Gillett; Mary-Jane Mastrandrea; Jessica FrischCase IVEY-9B09B004-EAccounting and ControlBiovail was a large international pharmaceutical company with reported revenues of $788 million. Banc of America has issued a research report which indicates that Biovail Corporation's financial statements raised a number of issues that warrant caution for investors, and as a result, Biovail's stock was given a sell rating by Banc of America. A member of Biovail's audit committee is preparing for an upcoming audit meeting and considers the implic...Starting at €8.20